Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
American Journal of Obstetrics and Gynecology|December 3, 2014
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse modelsErnst Lengyel, Lacey M Litchfield, Anirban K Mitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2023
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer PatientsSara M Tolaney, Shom Goel, Jorge Nadal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 InhibitorsXi Rao, Yongmei Chen, Julie Beyrer, et al.
The Journal of Biological Chemistry|May 14, 2015
Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma CellsYun Teng, Brandie N Radde, Lacey M Litchfield, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 24, 2010
Socioeconomic status and bone health in community-dwelling older men: the CHAMP StudyI Nabipour, R Cumming, D J Handelsman, et al.
Frontiers in Oncology|March 27, 2025
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b studySara M Tolaney, Komal Jhaveri, Teresa Helsten, et al.
Cell Reports|December 19, 2019
Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal CrosstalkPeter C Hart, Hilary A Kenny, Niklas Grassl, et al.
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Acta Crystallographica. Section D, Structural Biology|September 25, 2023
Increasing the bulk of the 1TEL-target linker and retaining the 10×His tag in a 1TEL-CMG2-vWa construct improves crystal order and diffraction limitsParag L Gajjar, Maria J Pedroza Romo, Celeste M Litchfield, et al.
Pageof 7